Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,590.38% | 96.77% | 79.89% | -390.63% | 19.78% |
| Total Depreciation and Amortization | 165.87% | -246.75% | -6.23% | 11.07% | 165.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.23% | 923.83% | -83.81% | 1,005.06% | -92.82% |
| Change in Net Operating Assets | -1,380.12% | -360.26% | -108.26% | 137.56% | -847.19% |
| Cash from Operations | -200.05% | 87.30% | -31.96% | 352.49% | -157.89% |
| Capital Expenditure | -43.90% | -796.88% | 16.88% | 73.54% | 21.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | -103.43% | 37,762.50% | 16.88% | 92.30% | -69.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 89.64% | -- | 100.00% | -170.42% | -- |
| Issuance of Common Stock | -86.40% | 99.46% | -9.20% | 244.07% | 12.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -313.73% | 2,354.45% | -0.53% | 86.06% | -692.44% |
| Cash from Financing | 102.21% | -11,938.40% | 104.61% | -84.94% | -30,200.00% |
| Foreign Exchange rate Adjustments | 120.84% | -542.70% | 211.22% | 22.98% | -247.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,158.71% | -113.47% | 62.44% | 157.85% | -216.32% |